查看購物車
  • Simplified Chinese
  • Japanese
  • Korean
青光眼治療藥的全球市場(2025年):2024年～2030年的分析
市場調查報告書
商品編碼
1700500

青光眼治療藥的全球市場(2025年):2024年～2030年的分析

2025 Glaucoma Pharmaceuticals Market Report: Global Analysis for 2024 to 2030
出版日期: | 出版商: Market Scope, LLC | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

新到信息

全球青光眼藥物市場（2025 年）包括新的區域銷售預測，其中考慮到美元兌其他主要貨幣的走強，以及對青光眼盛行率和診斷的最新分析。

報告還提供了美國和日本仿製藥和原研藥按藥品類別劃分的市場佔有率分析、美國和西歐按一線和伴隨藥物劃分的處方分層，以及西歐眼科醫生對藥物輸送持久性的調查數據。

我們也提供最新的青光眼藥物管道分析、正在進行的臨床試驗的最新情況以及區域經濟指標的回顧。

《全球青光眼藥物市場（2025 年）》分析了全球和區域青光眼藥物市場，強調了未來成功的主要趨勢和關鍵推動因素。本報告對品牌前列腺素、仿製前列腺素、β受體阻斷劑、碳酸酐酶抑制劑、α激動劑、固定組合藥物、NO供體和Rho激酶抑制劑進行了2030年的預測。該報告還涵蓋了目前正在開發的 30 多種候選藥物，並對管道產品進行了廣泛的討論。此外，報告還介紹了25家青光眼製藥公司，討論了它們的產品、戰略市場地位、背景和前景。

內容

本報告分析了目前的青光眼藥物市場，並預測了未來五年的市場表現。全球市場分析基於八個區域/經濟類別（美國、西歐、日本、其他富裕國家、中國、印度、拉丁美洲和世界其他地區），也用於提供全球疾病盛行率預測。此外，該報告還探討了有關疾病過程、青光眼人群、青光眼治療和其他各種主題的數據和信息，為讀者理解這一眼科領域提供深度和背景。

主要內容

  • 青光眼的類型和風險因素
  • 疾病的診斷與治療
  • 青光眼醫療保健提供者（包括眼科醫師和視光師）的全球視角
  • 全球疾病流行預測（5年）
  • 市面上的青光眼藥物及其作用機制
  • 仿製藥與品牌藥及其對市場的影響
  • 青光眼藥物研發管線
  • 生產和銷售青光眼治療藥物的公司簡介
簡介目錄

What's New:

The "2025 Glaucoma Pharmaceuticals Market Report" features new regional sales forecasts that consider appreciation of the dollar against other major currencies and an updated analysis of the prevalence and diagnosis of glaucoma.

The report now includes market share analysis of generics and branded drugs by drug class in the United States and Japan, prescription stratification by first-line and adjunctive use in the United States and Western European countries, and survey data on Western European ophthalmologists' plans for sustained drug delivery.

It also provides updated analysis of the glaucoma pharmaceutical pipeline, gives updates on ongoing clinical trials, and reviews regional economic indicators.

The "2025 Glaucoma Pharmaceuticals Market Report" analyzes the global and regional markets for glaucoma pharmaceuticals, identifying important trends and key factors for future success. The report provides forecasts through 2030 for branded prostaglandins, generic prostaglandins, beta blockers, carbonic anhydrase inhibitors, alpha agonists, fixed combo drugs, NO-donating compounds, and Rho-kinase inhibitors. The report also extensively discusses pipeline products, covering over 30 drug candidates that are currently under development. Additionally, 25 glaucoma pharmaceutical companies are profiled, with discussion of their products, strategic market position, background, and outlook.

Contents:

This report provides analysis of current markets for glaucoma medications and forecasts market performance over the next five years. The global market is analyzed based on Market Scope's eight regional/economic categories (the US, Western Europe, Japan, Other Wealthy Nations, China, India, Latin America, and Rest of World), and also uses these categories in global forecasts for disease prevalence. In addition, the report explores data and information on the disease process, glaucoma populations, glaucoma care, and a range of additional topics intended to provide depth and context to the reader's understanding of this ophthalmic segment.

Coverage includes:

  • Types of glaucoma and risk factors.
  • Diagnosis and treatment of the disease.
  • A global view of glaucoma care providers, including ophthalmologists and optometrists.
  • Current estimates and five-year forecasts for disease prevalence worldwide.
  • Glaucoma medications in the marketplace and their mechanisms of action.
  • Discussion of generic versus branded drugs and their market impact.
  • The development pipeline for glaucoma pharmaceuticals.
  • Profiles of companies making and marketing glaucoma medications.